Drugs & Therapy Perspectives

, Volume 26, Issue 9, pp 6–9 | Cite as

Cerebrolysin®: a guide to its use in dementia

Drug and Profile Reports

Cerebrolysin® is a brain-derived peptide preparation with pharmacodynamic properties that are similar to those of endogenous neurotrophic factors. In patients with Alzheimer’s disease or vascular dementia, Cerebrolysin® improved global outcome measures and cognitive ability and was generally well tolerated.

What is the rationale for developing the drug?

Dementia, a progressive decline in mental ability that affects memory, thinking, judgement and personality, is a leading cause of disability in the elderly.[ 1] The two most common causes of dementia are:[ 1]
  • Alzheimer’s disease (≈50–70% of cases). An age-related neurodegenerative disorder that is usually associated with a gradual decline in cognitive function

  • Vascular dementia (≈30% of cases). Can develop after successive strokes, small vessel disease or because of other mechanisms. Often has a rapid onset.

In general, most treatments for dementia (including the widely used cholinesterase inhibitors) do not reverse or halt disease...


  1. 1.
    Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging 2009; 26(11): 893–915PubMedCrossRefGoogle Scholar
  2. 2.
    Cerebrolysin® solution for injection: summary of product characteristics. Unterach, Austria: Ever Neuro Pharma GmbH, 2009 DecGoogle Scholar
  3. 3.
    Bae C-Y, Cho C-Y, Cho K, et al. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000 Dec; 48(12): 1566–71PubMedGoogle Scholar
  4. 4.
    Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002 Jul; 109(7–8): 1089–1104PubMedCrossRefGoogle Scholar
  5. 5.
    Ruether E, Husmann R, Kinzler E, et al. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol 2001 Sep; 16(5): 253–63PubMedCrossRefGoogle Scholar
  6. 6.
    Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol 2006 Jan; 13(1): 43–54PubMedCrossRefGoogle Scholar
  7. 7.
    Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. Epub 2010 May 25Google Scholar
  8. 8.
    Ruether E, Alvarez XA, Rainer M, et al. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin®. J Neural Transm 2002; 62 Suppl.: 265–75Google Scholar
  9. 9.
    Alvarez A, Cacabelos R, Aleixandre M, et al. Synergistic treatment effects with Cerebrolysin and donepezil: results from a randomized, double-blind, multicenter trial to compare safety and efficacy of Cerebrolysin, donepezil and a combination of both in patients with probable Alzheimer’s disease [abstract]. International Conference on Alzheimer’s Disease; 2009 Jul 11–16; ViennaGoogle Scholar
  10. 10.
    Alvarez XA, Cacabelos R. Integrated clinical study report (protocol EBE031010). A randomized, double-blind, clinical trial to compare the safety and efficacy of a Cerebrolysin and Aricept (donepezil) and a combination therapy in patients with probable Alzheimer’s disease. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Nov 27. (Data on file)Google Scholar
  11. 11.
    Gavrilova SI, Kolykhalov IV, Korovaitseva GI, et al. ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer’s disease [in Russian]. Zh Nevrol Psikhiatr Im SS Korsakova 2005; 105(4): 27–34Google Scholar
  12. 12.
    Guekht A, Moessler H, Doppler E, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial [abstract plus poster]. 9th International Conference for Alzheimer’s and Parkinson’s Disease; 2009 Mar 11–15; PragueGoogle Scholar
  13. 13.
    Gusev EI. Integrated clinical study report (protocol EBE-RU-051201). A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with vascular dementia. Unterach, Austria: EBEWE Neuro Pharma GmbH, 2008 Aug 18. (Data on file)Google Scholar
  14. 14.
    Vereschagin NV, Nekrasova EM, Lebedova NV, et al. Mild forms of multi-infarct dementia: effectiveness of cerebrolysin [in Russian]. Sov Med 1991; (11): 6–8Google Scholar
  15. 15.
    Xiao S, Yan H, Yao P. The efficacy of cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial. The Cerebrolysin Study Group. Hong Kong J Psychiatry 1999; 9(2): 13–9Google Scholar
  16. 16.
    Muresanu DF. The influence of Cerebrolysin on cognitive performances in patients suffering from vascular dementia. Unterach, Austria: EBEWE Pharmaceuticals Ltd, 1999Google Scholar

Copyright information

© Adis Data Information BV 2010

Personalised recommendations